Bausch + Lomb Corporation (BLCO) Acquires XIIDRA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at BofA Securities on new acquisition
July 3, 2023 6:53 AM EDTBofA Securities analyst Craig Bijou raised the price target on Bausch & Lomb Corp. (NYSE: BLCO) to $23.00 (from $19.00) while maintaining a Buy rating.
The analyst is positive on the acquisition of Novartis dry eye disease (DED) drug.
"We see the deal as a meaningful... More
Bausch + Lomb Corporation (BLCO) shares surge on $2.5bn deal to acquire XIIDRA
June 30, 2023 11:19 AM EDTBausch + Lomb Corporation (NYSE: BLCO) shares surged Friday after the company announced a deal to acquire XIIDRA from Novartis for up to $2.5 billion.
BLCO shares are currently up more than 5% at $20.20 after initially hitting a high of $21.95 per share.
The company, through an affiliate, will acquire XIIDRA, libvatrep, and AcuStream in a deal worth up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up... More
